Sarclisa savings card: as little as $0 a treatment with commercial insurance

Sarclisa is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Sarclisa is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameSarclisa

Authorized genericisatuximab

Regular genericisatuximab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Sarclisa?

The original

–

Brand nameThe maker’s card

CareASSIST Copay Program

Savings card from Sanofi

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 a treatment

Or call 1-833-930-2273.

In the maker’s words

“If you have commercial or private insurance, you could pay as little as $0 for out-of-pocket costs (copays, coinsurance, and insurance deductibles) for your SARCLISA ESCENA or SARCLISA medication through the CareASSIST Copay Program.”

From the maker’s offer on sanoficareassist.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Sarclisa itself, from the same company, sold without the brand name, and usually for less. For now Sarclisa is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Sarclisa is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Multiple myeloma

What the FDA label says

SARCLISA is a CD38-directed cytolytic antibody indicated:

in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor.
in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
in combination with bortezomib, lenalidomide and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).

Source: the FDA label for Sarclisa (Sanofi-Aventis U.S. LLC), July 7, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/sarclisa/